Ignite Creation Date:
2025-12-25 @ 5:08 AM
Ignite Modification Date:
2026-04-28 @ 8:04 PM
Study NCT ID:
NCT06283927
Status:
RECRUITING
Last Update Posted:
2024-02-28
First Post:
2024-02-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Sponsor:
Jasper Gerritsen
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Glioblastoma | View |
| None | Glioblastoma Multiforme | View |
| None | Glioblastoma, IDH-wildtype | View |
| None | Glioblastoma Multiforme of Brain | View |
| None | Glioblastoma Multiforme, Adult | View |
| None | Recurrent Glioblastoma | View |
| None | Astrocytoma, Malignant | View |
| None | Astrocytoma of Brain | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Glioblastoma | View |
| None | Radiotherapy | View |
| None | Chemotherapy | View |
| None | Re-resection | View |
| None | Resection | View |
| None | Overall survival | View |
| None | Progression-free survival | View |
| None | Neurological morbidity | View |
| None | Safety | View |
| None | Serious Adverse Events | View |
| None | Quality of life | View |